KSHV-VL differences in the first flare and remission or end of treatment (patients with concurrent PEL) in all patients, patients with MCD alone, and patients with MCD and KS. Among patients with MCD and PEL with or without KS, this was the difference between flare to the end of multiagent chemotherapy for PEL.